TABLE 2.
Univariable and Multivariable Regression for Progression-Free Survival
| Variable | Univariable Regression | |||||
|---|---|---|---|---|---|---|
| dPCR | HPV-Seq | |||||
| HR (95% CI) | P | C-Index | HR (95% CI) | P | C-Index | |
| Age | 0.99 (0.96 to 1.02) | .400 | 0.56 | Same | ||
| Histology | ||||||
| Squamous cell carcinoma | Reference | Same | ||||
| Nonsquamous cell carcinoma | 1.18 (0.44 to 3.13) | .740 | 0.49 | |||
| 2018 FIGO stage | ||||||
| IB/II | Reference | Same | ||||
| III/IVA | 2.90 (1.20 to 7.01) | .020 | 0.63 | |||
| Detectable HPV ctDNA at the end of CRT | 2.53 (1.06 to 6.03) | .040 | 0.61 | 3.88 (1.30 to 11.57) | .010 | 0.65 |
| Detectable HPV ctDNA at 4-6 weeks post-CRT | 8.58 (3.56 to 20.71) | <.001 | 0.72 | 4.19 (1.76 to 9.98) | .001 | 0.68 |
| Detectable HPV ctDNA at 3 months post-CRT | 6.29 (2.71 to 14.59) | <.001 | 0.72 | 8.29 (3.38 to 20.34) | <.001 | 0.75 |
| Model | Multivariable Regression | |||||
|---|---|---|---|---|---|---|
| dPCR | HPV-Seq | |||||
| HR (95% CI) | P | C-Index | HR (95% CI) | P | C-Index | |
| 2018 FIGO stage III/IVA v IB/II | 3.12 (1.21 to 8.09) | .020 | 0.70 | 3.43 (1.32 to 8.89) | .010 | 0.73 |
| Detectable HPV ctDNA at the end of CRT | 2.44 (1.02 to 5.82) | .045 | 4.13 (1.38 to 12.34) | .010 | ||
| 2018 FIGO stage III/IVA v IB/II | 1.91 (0.69 to 5.27) | .210 | 0.80 | 3.06 (1.18 to 7.93) | .020 | 0.76 |
| Detectable HPV ctDNA at 4-6 weeks post-CRT | 6.79 (2.66 to 17.34) | <.001 | 3.86 (1.61 to 9.22) | .002 | ||
| 2018 FIGO stage III/IVA v IB/II | 1.84 (0.73 to 4.59) | .190 | 0.75 | 2.16 (0.88 to 5.33) | .090 | 0.78 |
| Detectable HPV ctDNA at 3 months post-CRT | 5.50 (2.32 to 13.04) | <.001 | 7.78 (3.15 to 19.24) | <.001 | ||
Abbreviations: CRT, chemoradiation; ctDNA, circulating tumor DNA; dPCR, digital polymerase chain reaction; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papilloma virus; HR, hazard ratio.